There have been promising developments in the treatment of NAFLD/NASH with the emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and pioglitazone. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.